Bildkälla: Stockfoto

IRLAB Therapeutics Q4 2022: Still Plenty of Value - Redeye

Redeye returns with a research update following the Q4 report and recent events in the company. We slightly adjust our base case and conclude that 2023 will be an important year, most notably to present the full mesdopetam data and regain investor confidence.

Redeye returns with a research update following the Q4 report and recent events in the company. We slightly adjust our base case and conclude that 2023 will be an important year, most notably to present the full mesdopetam data and regain investor confidence.
Börsvärldens nyhetsbrev
ANNONSER